Abstract
Antibody targeted therapy of cancer results in anti-antibody production which prevents repeated treatment. Cyclosporin A (CsA) has been used to suppress this response in patients treated with a radiolabelled antibody to carcinoembryonic antigen (CEA). Patients with CEA producing tumours received a minimum of two courses consisting of an injection of radiolabelled antibody and CsA, 24 mg kg-1 day-1, for 6 days; each course was given at 2 week intervals. Two weeks after the completion of the second course the mean human antimouse antibody (HAMA) levels were 3.5 micrograms ml-1 (s.d. 2.7) in 3 patients receiving CsA and 1,998 micrograms ml-1 (s.d. 387) in 3 patients not receiving the drug. Clearance of antitumour antibody was accelerated and tumour localisation absent when HAMA levels exceeded 30 micrograms ml-1. With lower levels of HAMA in the CsA-treated patients, further antitumour antibody accumulated in the tumour after each dose. Further therapy with antitumour antibody and CsA lead to the development of HAMA, but this was less than 25% of the amount in patients not given CsA. In this preliminary study up to 4 times as many doses of antitumour antibody could be usefully given when CsA was used. This increases the potential for effective antibody targeted therapy of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ledermann, J., Begent, R., Bagshawe, K. et al. Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer 58, 654–657 (1988). https://doi.org/10.1038/bjc.1988.279
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.279
This article is cited by
-
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
British Journal of Cancer (2015)
-
Current perspectives on therapeutic antibodies
Biotechnology and Bioprocess Engineering (2010)
-
Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
British Journal of Cancer (2009)
-
Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study
British Journal of Cancer (2002)
-
Human monoclonal antibody99mTc-88BV59: Detection of colorectal cancer, recurrent or metastatic disease and immunogenicity assessment
European Journal of Nuclear Medicine (1997)